ClinicalTrials.gov
public full text
Public Domain
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Physical Activity Oxidative Stress and Inflammation With Ageing#868197
- Evaluation of Fiit-ns® in Health-related Quality of Life Improvement in Overweight and Obese Subjects#835097
- Effect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults#1088212
- Mitochondrial Substrate Utilization in the Diabetic Human Heart#876285
- Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure#910283
Record · ID 846430
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive